Altimmune ALT
NASDAQ ALT
$2.73 -0.03 (-1.09%)
At close: Oct 2, 2026 · 4:00 PM EDT

Altimmune (ALT) Asset Writedowns and Impairment (2017 - 2026)

Updated

Altimmune (ALT) posted Asset Writedowns and Impairment of $800,000 for Q2 2026, up 14.3% from the prior quarter.

Analysis

Altimmune (ALT) Asset Writedowns and Impairment (2017 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Asset Writedowns and Impairment at Altimmune was $4.8 million; for FY2023, it came in at $12.42 million.

  • Annual Asset Writedowns and Impairment shows a five-year compound annual growth rate of -13.0% (FY2018 to FY2023).
  • In prior years, Altimmune's Asset Writedowns and Impairment was $11.37 million in FY2021 and $1 million in FY2019 (-96.0%).
  • The Q2 2026 figure stands as the highest quarterly Asset Writedowns and Impairment since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Altimmune 530.91 Mn 530.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 800,000.00
Mar 31, 2026 700,000.00
Dec 31, 2021 3.30 Mn
Jun 30, 2021 8.07 Mn
Sep 30, 2019 1.00 Mn
Dec 31, 2018 24.45 Mn
Mar 31, 2018 490,676.00
Dec 31, 2017 9.32 Mn
Sep 30, 2017 26.60 Mn
API Access

Altimmune Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=ALT&period=max&api_key=YOUR_API_KEY